Search the web
Welcome, Guest
[Sign Out, My Account]
EDGAR_Online

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
AEGR > SEC Filings for AEGR > Form 8-K on 30-Jul-2014All Recent SEC Filings

Show all filings for AEGERION PHARMACEUTICALS, INC.

Form 8-K for AEGERION PHARMACEUTICALS, INC.


30-Jul-2014

Change in Directors or Principal Officers, Financial Statements an


Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On July 18, 2014, the board of directors of Aegerion Pharmaceuticals, Inc. ("Aegerion" or the "Company") appointed Craig Fraser as Chief Operating Officer ("COO"), effective August 1, 2014. In this role, Mr. Fraser will serve as the Company's principal operating officer, and he will continue as an executive officer of the Company. In connection with his promotion to COO, the Company anticipates that it will enter into an amended and restated employment agreement with Mr. Fraser, and, on August 1, 2014 (the "Grant Date"), Mr. Fraser will receive a grant of options to purchase a total of up to 50,000 shares of the Company's common stock, which options shall vest and become exercisable with respect to 12,500 shares on the first anniversary of the Grant Date, with the remaining shares vesting ratably each month over the subsequent three years, such that all options will be fully vested on the fourth anniversary of the Grant Date.

Mr. Fraser, 50, has served as Aegerion's President, U.S. Commercial & Global Manufacturing and Supply Chain since September 2012. From October 2011 to September 2012, Mr. Fraser served as Aegerion's President, U.S. Before joining Aegerion, Mr. Fraser was Vice President, Global Disease Areas at Pfizer Inc. from November 2009 to August 2011, where he was responsible for the commercial development and global marketing for the Specialty Cardiovascular, Anti-Bacterial, Anti-Fungal, Gastrointestinal and Anti-Viral disease areas, and managed a portfolio of six products totaling over $3 billion in revenue and multiple new products in development. Prior to joining Pfizer, Mr. Fraser was Vice President and Global Business Manager at Wyeth from December 2007 to November 2009, where he led the institutional/infectious disease business. Before that, Mr. Fraser held several commercial positions at Johnson & Johnson, most recently as Vice President, Commercial Operations and Oncology Sales and Marketing. Previously, he was Gastroenterology Franchise lead as well as National Sales Director of the Immunology and Cardiovascular business units at Centocor.

There is no arrangement or understanding between Mr. Fraser and any other person pursuant to which Mr. Fraser was selected as the Company's COO. Except as described herein, there are no existing or currently proposed transactions to which the Company or any of its subsidiaries is a party and in which Mr. Fraser has a direct or indirect material interest. There are no family relationships between Mr. Fraser and any of the directors or officers of the Company or any of its subsidiaries.



Item 9.01 Financial Statements and Exhibits.

(d) Exhibits:

99.1 Press Release dated July 30, 2014.


  Add AEGR to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for AEGR - All Recent SEC Filings
Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.